Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

Forward-Looking Statements Statements included in this press release and Cadence's conference call that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: Cadence's plan to submit a supplemental new drug application to the FDA for OFIRMEV in flexible plastic bags in the second half of 2013; the company's belief that it will be able to meet its customers' increasing requirements for OFIRMEV; and the company's guidance regarding net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and its ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current intellectual property litigation with the parties that have submitted abbreviated new drug ap
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 LifeCell Dx ... be able to get an Advanced Semen Analysis before ... blaming and guessing are all risk factors for struggling ... woman is the source of the infertility. Infertility is ... Dx has the simplest, least complicated and inexpensive ...
(Date:3/5/2015)... Research Triangle Park, NC (PRWEB) March 05, 2015 ... Entegrion, Inc., announced that Pierre Noel, M.D., Professor ... been elected to the Company’s Board of Directors. ... Mowell said, “We are extremely fortunate to have ... with the country’s leading healthcare organization, join Entegrion’s ...
(Date:3/5/2015)... SAN DIEGO , March 5, 2015  In ... Marketwired in Miami, FL on ... company are both of strong financial health and their ... as clinical research has indicated. Furthermore, Impeto prefers to have ... There are more than 40 articles written ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... , 3.75% Convertible Senior Notes due May 1, ... per $1,000 principal amount or approximately $5.72 per share, effective ... note is adjusted in connection with the regular quarterly dividend ... stockholders who own shares of PDL on March 5, 2015, the ...
Breaking Biology Technology:LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... Chief Executive,Officer and a member of the Board of ... President and Chief Executive Officer of,Neurocrine and will continue ... "While this was a very difficult decision for ...
... 14 VIRxSYS Corporation, a,privately held company developing ... Corporation, a privately-owned biotechnology company,focused on the manufacture ... have agreed to settle the pending litigation between,the ... and counterclaims,asserted in the lawsuit, which has been ...
... Patients are ... in the U.S., REHOVOT, Israel and NORTH BRUNSWICK, ... ROSG ), a leader,in the development of microRNA-based diagnostics ... with the Henry Ford,Health System in Detroit, Michigan, to ...
Cached Biology Technology:Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer 2VIRxSYS and Lentigen Announce Litigation Settlement 2Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 2Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 3Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer 4
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle ... Annual estimates and forecasts are provided for the period 2013 ... these markets. Market data and analytics are derived from primary ...
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2
... Washington, D.C. (September 14, 2010) -- Because one ... protein molecules is producing good isolated single crystals, improved ... of genomics and pharmaceutical research. Research reported ... fluorescence correlation spectroscopy (FCS) to investigate the processes at ...
... Biological Sciences Research Council,(BBSRC) have discovered key plant enzymes that ... non-edible parts of plants difficult to extract. The findings, published ... , can be used to improve the viability of sustainable ... The team based at the University of Cambridge, and now ...
... genetic study to compare nuclear DNA of endangered Antillean ... as separate subspecies. Belize,s manatees, however, were found to ... long-term genetic viability. The Central American country of ... manatees and is touted by biologists for its potential ...
Cached Biology News:How do your crystals grow? 2Biofuel from inedible plant material easier to produce following enzyme discovery 2Manatee subspecies genetically confirmed, but diversity challenge looms 2Manatee subspecies genetically confirmed, but diversity challenge looms 3
... Perhaps sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems and ... for your hard work and endeavour! Bring us ... and market it internationally. We work under ISO ...
... Diluted Antiserum for RIA, Host: Rabbit ... Immunology Products, Host: Rabbit Antigen ... peptide and 1 2 ... (rat) (H-9295) and ([ 1 2 ...
... vaccinia virus is a type I eukaryotic ... superhelical turns (also called right- and left-handed ... of the reaction is a covalently closed, ... superhelical turns. DNA Topoisomerase I does not ...
...
Biology Products: